<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
MGC Pharmaceutical Ltd said it achieved its strongest quarterly sales to date in the three months to end-December, driven by its COVID-19 treatment ArtemiC. The phytomedicines company also announced that the phase II clinical trial for Cognicann, its Investigational Medicinal Product (IMP) designed to treat patients with dementia and Alzheimer’s disease, which is undertaken by the University of Notre Dame in Perth, Western Australia, has been delayed after logistics problems impacted the supply of the product to into Australia, while COVID-19 restrictions have hampered access to trial participants.
...read full article on Proactive Investors
